Biogen Idec's 'Plegridy' therapy for multiple sclerosis delayed by FDA

Home › Biogen Idec's 'Plegridy' therapy for multiple sclerosis delayed by FDA

Two new multiple sclerosis pills have hit the market and a third is on the way to replace shots with potentially serious side effects.

30.06	Weekly Recap: Rockline Wins WOW Innovation Award, Hospeco Purchases Nuance Solutions & More
30.06	Eastern North Pacific Tropical Weather Outlook
30.06	Hurricane Beryl Graphics
30.06	Hurricane Beryl Public Advisory Number 7A
30.06	Summary for Hurricane Beryl (AT2/AL022024)
30.06	Eastern North Pacific Tropical Weather Outlook
30.06	Atlantic Tropical Weather Outlook
30.06	Hurricane Beryl Forecast Discussion Number 7
More »

je.st